Redeye provides an update on ChromoGenics following the company's Q4 2023 results. A weak quarter closed a tough 2023. But with recent successful capital increase, and a few good projects in the pipeline, 2024 looks promising.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

© Modular Finance, source Nordic Press Releases